India markets closed
  • BSE SENSEX

    53,823.36
    +872.73 (+1.65%)
     
  • Nifty 50

    16,130.75
    +245.60 (+1.55%)
     
  • Dow

    35,008.87
    +170.71 (+0.49%)
     
  • Nasdaq

    14,721.43
    +40.36 (+0.27%)
     
  • BTC-INR

    2,837,082.25
    -110,762.75 (-3.76%)
     
  • CMC Crypto 200

    932.21
    -11.23 (-1.19%)
     
  • Hang Seng

    26,194.82
    -40.98 (-0.16%)
     
  • Nikkei

    27,641.83
    -139.19 (-0.50%)
     
  • EUR/INR

    88.0669
    -0.2089 (-0.24%)
     
  • GBP/INR

    103.1634
    -0.1292 (-0.13%)
     
  • AED/INR

    20.1710
    -0.0280 (-0.14%)
     
  • INR/JPY

    1.4660
    -0.0003 (-0.02%)
     
  • SGD/INR

    54.9220
    -0.0510 (-0.09%)
     

GV Prasad of Dr Reddy's Laboratories on the partnership with Russian Direct Investment Fund & more

In an exclusive conversation with ET NOW, GV Prasad, Co-chairman & MD, Dr. Reddy's Laboratories speaks on Remlivid settlement, DRL-RDIF partnership, Sputnik vaccine tie-up and future acquisition plans and a lot more. Revlimid is an important drug settlement for the company, and it will be a significant product for DRL says Dr GV Prasad.

He remains confident that India is a dominant sector in the generics market and the healthcare industry will favour generics going forward as the government has recognised Pharma sector's importance after the COVID crisis. Speaking on growth, the DRL leader says they are aiming to enter new segments in Russia & DRL is responsible for Indian trials of Sputnik-V vaccine, the company is always looking for acquisitions in key markets like India, while the company is not overly dependent on China. He sees a dramatic change in the product mix in 3-5 years.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting